Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses
Christopher LD McMillan, Stacey TM Cheung, Naphak Modhiran, James Barnes, Alberto A Amarilla, Helle Bielefeldt-Ohmann, Leo Yi Yang Lee, Kate Guilfoyle, Geert van Amerongen, Koert Stittelaar, Virginie Jakon, Celia Lebas, Patrick Reading, Kirsty R Short, Paul R Young, Daniel Watterson, Keith J Chappell
NPJ VACCINES | NATURE PORTFOLIO | Published : 2021
Influenza viruses cause a significant number of infections and deaths annually. In addition to seasonal infections, the risk of an influenza virus pandemic emerging is extremely high owing to the large reservoir of diverse influenza viruses found in animals and the co-circulation of many influenza subtypes which can reassort into novel strains. Development of a universal influenza vaccine has proven extremely challenging. In the absence of such a vaccine, rapid response technologies provide the best potential to counter a novel influenza outbreak. Here, we demonstrate that a modular trimerization domain known as the molecular clamp allows the efficient production and purification of conforma..View full abstract
Awarded by National Health and Medical Research Development grant from the Australian Government
This work was supported by the National Health and Medical Research Development grant from the Australian Government (AP1156063) and the Coalition for Epidemic Preparedness Innovations (CEPI). CLDM was supported by the Australian Postgraduate Award. We thank the staff at the AIBN animal facility for providing technical guidance during the mouse experiments. We also thank the biotechnicians, laboratory technicians and the rest of the team at Viroclinics Xplore for their work on the ferret challenge studies.